News

The phase I trial with NGX424 will enroll approximately 90 healthy male volunteers at one center in the US, and will evaluate the local and systemic tolerability, safety

Eyetech stockholders will receive $15 per share in cash and 0.12275 of OSI shares for each share of Eyetech owned as of the closing date. OSI completed the

Orphan designation has been granted on the basis of Bronchitol’s potential to treat cystic fibrosis, a genetic disease which, for the patient, is characterized by recurring respiratory complications.

The approval was based on the results of the largest prospective, randomized and double-blind clinical trial ever conducted in diabetic patients with moderate to severe complicated foot infection.

SCH 503034 was shown to have potential in treating the disease both on its own and in combination with Peg-Intron (peginterferon alfa-2b). Hepatitis C virus (HCV) genotype 1

The trial tested whether glucosamine and chondroitin used separately or in combination, and in comparison to placebo and celecoxib, are effective in reducing pain and improving functional ability

Central arterial blood pressure is the pressure in the aorta, which determines the stress and damage on the heart and central vessels. Lower central arterial blood pressure readings

The trials will test the synergistic effect of the combination therapy in the treatment of patients with advanced myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). HDAC inhibitors,

The extension data, presented for at the American Society of Nephrology 38th annual meeting, mirror earlier results in dialysis patients, suggesting that CERA provides consistent anti-anemia activity in